Bioventus Reports Surge in Sales, Profitability, and Promise for 2025

March 11, 2025

DENVER, Colo., Mar 11, 2025 (247marketnews.com)- Bioventus (NASDAQ:BVS) reported fourth quarter and full-year 2024 financial performance that blew past expectations. The results included a 13.5% spike in Q4 worldwide revenue, hitting $153.6 million, fueled by double-digit growth in its Pain Treatments and Surgical Solutions segments. For the full year, revenue soared to $573.3 million, up 11.9% from 2023, with organic growth clocking in at 14.4%. The Company’s 2025 guidance signals more horsepower to come.

Sales growth accelerated, with Pain Treatments jumping 18.7% in the U.S. to $62.8 million and Surgical Solutions climbing 16.8% to $46.4 million, while Restorative Therapies held steady at $26.0 million. Internationally, Pain Treatments grew 3.2% to $6.4 million, Surgical Solutions surged 22.9% to $7.3 million, and Restorative Therapies rose 5.9% to $4.7 million. Total global net sales hit $153.6 million, a 13.5% leap (13.4% in constant currency) from $135.4 million in Q4 2023. Gross margin expanded 310 basis points and adjusted gross margin increasing 230 basis points, underpinned by operational finesse. Cash flow from operations soared 86.3% to $19.3 million.

The full-year picture is just as compelling. Worldwide revenue reached $573.3 million, an 11.9% climb from $512.3 million in 2023, with U.S. sales up 12.7% to $506.8 million and international sales advancing 6.4% to $66.5 million. Pain Treatments led the charge stateside with an 18.7% increase to $234.9 million, Surgical Solutions grew 18.2% to $167.7 million, while Restorative Therapies dipped 5.3% to $104.2 million—a shift partly due to the SonicOne product’s reclassification to Surgical Solutions in Q1 2024, reflecting its soft-tissue management alignment. Internationally, Pain Treatments rose 15.3% to $26.4 million, Surgical Solutions gained 9.3% to $21.5 million, and Restorative Therapies eased 6.8% to $18.6 million. O

Q4 net loss from continuing operations shrank to $0.3 million, down from $7.7 million in 2023, erasing the per-share loss of Class A common stock (from $(0.10) last year) to break even. Non-GAAP earnings per share jumped to $0.15 from $0.07, while adjusted EBITDA from continuing operations soared 28.3% to $28.3 million from $22.0 million. For the year, net loss from continuing operations improved to $43.8 million from $121.2 million, cutting per-share loss to $(0.52) from $(1.54), with non-GAAP EPS leaping to $0.49 from $0.02. Adjusted EBITDA climbed 22.5% to $108.9 million, fueled by revenue gains and margin expansion—a glow-up from 2023’s $88.9 million.

The company notched five straight quarters of double-digit growth in Pain Treatments and Surgical Solutions, a streak that powered that 28.3% Q4 EBITDA boost. It offloaded its Advanced Rehabilitation Business in Q4 for $24.7 million, sharpening focus on core strengths, and slashed long-term debt by $48.3 million, bolstering liquidity.

Bioventus’s 2025 guidance is bullish. Net sales are pegged at $560 million to $570 million, reflecting organic growth of 6.1% to 8.0%—even after factoring out the divested unit’s $45.4 million 2024 haul. Adjusted EBITDA is forecast at $112 million to $116 million, a 100-basis-point margin jump from 2024’s 19.0%, while non-GAAP EPS is slated for $0.64 to $0.68, up 30.6% to 38.8%.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (BVS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.